This report evaluates the analytical validity, clinical validity, and clinical utility of the Oncotype DX Breast Recurrence Score test.
Publications
Hayes Publications are available through the Hayes Knowledge Center, a portal to world-class research and unbiased analyses on the clinical, financial, and risk impacts of emerging, controversial, and disruptive healthcare technologies.Every Hayes publication is developed by multidisciplinary teams of clinicians and scientists using rigorous methods grounded in internally recognized standards for systematic review and Health Technology Assessment. Learn more about these evidence resources and see sample titles below.
See below for some of our recent publications.
Acellular Skin Substitutes for Chronic Foot Ulcers in Adults with Diabetes Mellitus
Focus of the Report: This report compares the effectiveness and safety of acellular skin substitutes as an addition to standard wound care (SWC) compared with SWC alone and compared with the use of cellular skin substitutes to treat chronic or nonhealing diabetic foot ulcers (DFU) in adults with diabetes mellitus (DM).
Expandable Interbody Cages for Lumbar Spinal Fusion
Focus of the Report: This report focuses on expandable interbody cages (EIC) for lumbar fusion in patients with degenerative disc disease (DDD).
Technology Description: Interbody fusion procedures involve the removal of a pathologic disc and insertion of interbody cages and bone grafts…
Oral Immunotherapy with Palforzia (peanut allergen powder-dnfp) for the Management of Peanut Allergy
Focus of the Report: Use of oral immunotherapy (OIT) with Palforzia (formerly AR101) for the management of peanut allergy.
Technology Description: Palforzia (peanut allergen powder-dnfp) is an oral immunotherapy (OIT) treatment comprising a proprietary formulation of peanut protein man…
Micro-Ultrasound for Diagnosis of Prostate Cancer
Focus of the Report: In its application to prostate biopsy, micro-ultrasound (mUS), also known as high-resolution ultrasound (US), not only provides guidance for the biopsy needle but also allows identification of features that cannot be revealed by conventional US. Thus, mUS has the potential to identify cancerous lesions that might otherwis…
Micro-Ultrasound for Diagnosis of Prostate Cancer
Focus of the Report: In its application to prostate biopsy, micro-ultrasound (mUS), also known as high-resolution ultrasound (US), not only provides guidance for the biopsy needle but also allows identification of features that cannot be revealed by conventional US. Thus, mUS has the potential to identify cancerous lesions that might otherwis…
Pharmacogenetic and Pharmacogenomic Testing to Improve Outcomes Related to Opioid Use Disorder
This report evaluates the clinical utility of pharmacogenetic and pharmacogenomic testing for (1) gene variants to predict risk of opioid dependency in patients being treated for pain or (2) gene variants to improve treatment of patients with diagnosed opioid use disorder (OUD).
Pharmacogenetic and Pharmacogenomic Testing to Improve Outcomes Related to Opioid Use Disorder
This report evaluates the clinical utility of pharmacogenetic and pharmacogenomic testing for (1) gene variants to predict risk of opioid dependency in patients being treated for pain or (2) gene variants to improve treatment of patients with diagnosed opioid use disorder (OUD).
Oncotype DX Breast Recurrence Score for Lymph Node–Negative Patients (Genomic Health Inc.)
This report evaluates the analytical validity, clinical validity, and clinical utility of the Oncotype DX Breast Recurrence Score testfor patients diagnosed with estrogen receptor–positive, human epidermal growth factor 2–negative, and node-negative invasive breast cancer.
Trodelvy (sacituzumab govitecan-hziy) for Metastatic Triple Negative Breast Cancer
Trodelvy (sacituzumab govitecan-hziy) is an intravenously administered antibody-drug conjugate (ADC) indicated for the treatment of adult patients with metastatic triple-negative breast cancer (mTNBC) who have received at least 2 prior therapies for metastatic disease. Trodelvy is the first FDA-approved ADC indicated for the treatment of TNBC.